Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has clinical-stage lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; and leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction It also has additional pre-clinical stage LVV programs include pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia; and infantile malignant osteopetrosis, a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone646-440-9100
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees33
Next Earnings Date8/14/2019 (Estimated)
OptionableOptionable
Rocket Pharmaceuticals (NASDAQ:RCKT) Frequently Asked Questions
What is Rocket Pharmaceuticals' stock symbol?
Rocket Pharmaceuticals trades on the NASDAQ under the ticker symbol "RCKT."
How were Rocket Pharmaceuticals' earnings last quarter?
Rocket Pharmaceuticals Inc (NASDAQ:RCKT) released its quarterly earnings data on Wednesday, May, 8th. The biotechnology company reported ($0.43) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.63) by $0.20. View Rocket Pharmaceuticals' Earnings History.
When is Rocket Pharmaceuticals' next earnings date?
What price target have analysts set for RCKT?
8 equities research analysts have issued twelve-month price objectives for Rocket Pharmaceuticals' stock. Their forecasts range from $22.00 to $39.00. On average, they expect Rocket Pharmaceuticals' stock price to reach $31.40 in the next year. This suggests a possible upside of 83.7% from the stock's current price. View Analyst Price Targets for Rocket Pharmaceuticals.
What is the consensus analysts' recommendation for Rocket Pharmaceuticals?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rocket Pharmaceuticals in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Rocket Pharmaceuticals.
What are Wall Street analysts saying about Rocket Pharmaceuticals stock?
Here are some recent quotes from research analysts about Rocket Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Rocket Pharmaceuticals, Inc. is an emerging, clinical-stage biotechnology company. It focused on developing first-in-class gene therapy treatment options for rare, undertreated diseases. Rocket Pharmaceuticals Inc., formerly known as Inotek Pharmaceuticals Corporation, is based in LEXINGTON, United States. " (5/22/2019)
- 2. Cowen Inc analysts commented, "Catalysts .Financial Rating — Buy Target Price — $124.00 FY18A EPS — $(2.50) Revenue — $5.0 FY19E Revenue — $0.0 Price ( 05/08/19 ): $70.23 52-Week Range: $110 – $54 1,692.5 Shr.O/S-Diluted (mm): 24.1 238,452 Dividend / Yield: $0.00 / 0.0% Cash (mm): $484 Price: Intraday 5-8-19." (5/8/2019)
- 3. William Blair analysts commented, "We believe this last point is key and de-risks the program as it progresses the expected clinical trial for RP- L102 using a refined manufacturing Process near term that is expected to enroll roughly 12 patients in the United States and EU. We believe the use of higher cell doses, transduction enhancers, and commercial-grade vectors in “Process B” will promote higher VCN (≥1) resulting in more clinically meaningful outcomes. Overall, we view the update as positive for the program." (5/1/2019)
Has Rocket Pharmaceuticals been receiving favorable news coverage?
News stories about RCKT stock have been trending somewhat negative on Wednesday, according to InfoTrie. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Rocket Pharmaceuticals earned a daily sentiment score of -1.2 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Rocket Pharmaceuticals.
Who are some of Rocket Pharmaceuticals' key competitors?
Some companies that are related to Rocket Pharmaceuticals include Global Blood Therapeutics (GBT), Uniqure (QURE), Agios Pharmaceuticals (AGIO), Arena Pharmaceuticals (ARNA), Amicus Therapeutics (FOLD), The Medicines (MDCO), Biohaven Pharmaceutical (BHVN), Reata Pharmaceuticals (RETA), Arrowhead Pharmaceuticals (ARWR), Intercept Pharmaceuticals (ICPT), PTC Therapeutics (PTCT), Emergent Biosolutions (EBS), Ligand Pharmaceuticals (LGND), Akcea Therapeutics (AKCA) and Myokardia (MYOK).
What other stocks do shareholders of Rocket Pharmaceuticals own?
Who are Rocket Pharmaceuticals' key executives?
Rocket Pharmaceuticals' management team includes the folowing people:
- Mr. Gaurav Shah, CEO, Pres & Director (Age 44)
- Mr. John C. Militello, Controller (Age 46)
- Ms. Kinnari Patel M.B.A., Pharm.D., PharmD, MBA, COO & Head of Devel. (Age 39)
- Dr. Claudine Prowse Ph.D., Sr. VP of Corp. Strategy & IRO
- Mr. Jonathan Schwartz, Chief Medical Officer (Age 55)
Who are Rocket Pharmaceuticals' major shareholders?
Rocket Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Marshall Wace North America L.P. (0.35%), Marshall Wace LLP (0.29%), Assenagon Asset Management S.A. (0.12%), Spark Investment Management LLC (0.06%), Rhumbline Advisers (0.06%) and TD Asset Management Inc. (0.05%). Company insiders that own Rocket Pharmaceuticals stock include David P Southwell, Gaurav Shah, Kinnari Patel, Naveen Yalamanchi and Rtw Investments, Lp. View Institutional Ownership Trends for Rocket Pharmaceuticals.
Which institutional investors are selling Rocket Pharmaceuticals stock?
RCKT stock was sold by a variety of institutional investors in the last quarter, including TD Asset Management Inc.. Company insiders that have sold Rocket Pharmaceuticals company stock in the last year include David P Southwell, Gaurav Shah and Naveen Yalamanchi. View Insider Buying and Selling for Rocket Pharmaceuticals.
Which institutional investors are buying Rocket Pharmaceuticals stock?
RCKT stock was purchased by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., Marshall Wace LLP, Spark Investment Management LLC, Assenagon Asset Management S.A., BNP Paribas Arbitrage SA, Rhumbline Advisers, Group One Trading L.P. and Mitsubishi UFJ Kokusai Asset Management Co. Ltd.. Company insiders that have bought Rocket Pharmaceuticals stock in the last two years include Kinnari Patel and Rtw Investments, Lp. View Insider Buying and Selling for Rocket Pharmaceuticals.
How do I buy shares of Rocket Pharmaceuticals?
Shares of RCKT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Rocket Pharmaceuticals' stock price today?
One share of RCKT stock can currently be purchased for approximately $17.09.
How big of a company is Rocket Pharmaceuticals?
Rocket Pharmaceuticals has a market capitalization of $859.44 million. The biotechnology company earns $-74,520,000.00 in net income (profit) each year or ($1.89) on an earnings per share basis. Rocket Pharmaceuticals employs 33 workers across the globe.View Additional Information About Rocket Pharmaceuticals.
What is Rocket Pharmaceuticals' official website?
How can I contact Rocket Pharmaceuticals?
Rocket Pharmaceuticals' mailing address is 350 FIFTH AVENUE SUITE 7530, NEW YORK NY, 10118. The biotechnology company can be reached via phone at 646-440-9100 or via email at [email protected]
MarketBeat Community Rating for Rocket Pharmaceuticals (NASDAQ RCKT)
MarketBeat's community ratings are surveys of what our community members think about Rocket Pharmaceuticals and other stocks. Vote "Outperform" if you believe RCKT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RCKT will underperform the S&P 500 over the long term. You may vote once every thirty days.
